Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Total Non-Current Liabilities of $525.3 million for Q1 2026, up 3.82% quarter-over-quarter from $506.0 million in Q4 2025.
Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Caris Life Sciences' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $525.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $525.3 million; the TTM figure through Mar 2026 stood at $525.3 million (changed N/A YoY), while the FY2025 annual figure was $506.0 million, down 4.4% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $525.3 million, up from $506.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $529.3 million in Q4 2024, with the low at $502.2 million in Q2 2025.
- The 3-year median for Total Non-Current Liabilities is $506.2 million (2025), against an average of $513.8 million.
- Peak annual rise in Total Non-Current Liabilities reached 4.4% in 2025, while the deepest fall reached 4.4% in 2025.
- Caris Life Sciences' Total Non-Current Liabilities stood at $529.3 million in 2024, then dropped by 4.4% to $506.0 million in 2025, then rose by 3.82% to $525.3 million in 2026.
- Business Quant data shows CAI's Total Non-Current Liabilities at $525.3 million in Q1 2026, $506.0 million in Q4 2025, and $506.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 584.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 584.41 Mn |
| Mar 31, 2026 | 525.30 Mn |
| Dec 31, 2025 | 505.97 Mn |
| Sep 30, 2025 | 506.21 Mn |
| Jun 30, 2025 | 502.15 Mn |
| Dec 31, 2024 | 529.28 Mn |